Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Phase 2TerminatedNCT00477087

Stanford University10 enrolled

Overview

The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.

This trial evaluates if the addition of GM-CSF to standard-of-care therapy after 1st-line docetaxel improves tumor control and survival. Because the 2 drugs have completely different mechanisms of action as well as non-overlapping metabolism, clinically significant drug-drug interactions are not anticipated, and therefore both drugs will be given at standard (approved) doses.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostatic Neoplasms

Interventions

MitoxantroneDRUG

Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.

GM-CSFDRUG

GM-CSF is a biologic response modifier, classified as a colony stimulating factor.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed written informed consent * Age ≥ 18 years * Histologically-confirmed adenocarcinoma of the prostate * Hormone-refractory prostate cancer * Failed 1st-line docetaxel-containing regimen * No prior immunotherapy including: * Vaccines * GM-CSF * Minimum prostate-specific antigen (PSA) \> 5 mg/dL and rising according to the PSA Consensus Criteria * Karnofsky Performance Status (KPS) \> 60% * Eastern Cooperative Oncology Group (ECOG) Performance Status \< 3 * Life expectancy \> 6 months Exclusion Criteria: * Concomitant hormonal therapy other than luteinizing hormone-releasing hormone (LHRH) agonist * Use of herbal products known to decrease PSA levels * Use of supplements or complementary medicines, except for: * Conventional multivitamin supplements * Selenium * Lycopene * Soy supplements * Vitamin E * Initiation of bisphosphonates within one month prior to enrollment or throughout the study * Any prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment * Major surgery or radiation therapy completed \< 4 weeks prior to enrollment * Any concomitant second malignancy other than non-melanoma skin cancer * Any concomitant serious infection * Any nonmalignant medical illness * Absolute neutrophil count (ANC) \< 1,500/µL * Platelet count \< 100,000 µL * Hemoglobin \< 8 mg/dL * Total bilirubin greater than 1.5 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN if no demonstrable liver metastases, or greater than 5.0 x ULN in presence of liver metastases * Ejection fraction \< 50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan * Noncompliance with study procedures

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Progression-free Survival (PFS)

Assessed as the time from the 1st dose of study drug to death or disease progression (increase \>25% over baseline PSA on 2 consecutive measurements 2 weeks apart, need for palliative therapy, formation/progression of new bone lesions, or decline of \>20% KPS)

Time frame: 18 months

Secondary Outcomes

Number of Participants With > 50% Decrease in Prostate-specific Antigen Levels (PSA Response)

Defined as the first evidence of a total serum PSA decline of \> 50% from baseline, maintained for at least 28 days, and confirmed with 2 consecutive measurements taken 2 weeks apart.

Time frame: 18 months

Overall Survival (OS)

Assessed as the time from the 1st dose of study drug to death.

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.